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ABSTRACT

Thyroid hormone(T3)induces GLUT4transporters and restores normal membranebound GLUT4 quantities in adipocytes and myocytes, induces thermogenesis, improves

glycemic status, and normalizes the metabolism ofTj-resistant db/db mice. The effect of
T3 on GLUT4transporter expression in +/db and db/db mice wasinvestigated by comparing
the cytoplasmic and membrane bound GLUT4 in adipocytes and myocytes from vehicletreated and Tj-treated animals, Total GLUT4 in adipocytes ofvehicle-treated db/db mice
was50% of+/db mice(D.886±0.31 vs. 1.99±0.37 OD units, p<0.01)but could be restored

to normal(1.928±0.21 OD units)with 500 ng T3/g BW. Cytoplasmic GLUT4 content of
adipocytes in vehicle-treated db/db mice was 50% less than +/db animals(0.624±0.22 vs.
1.488±0.36 OD units, p<O.Ol). However, T3 treatment (500 ng/g BW) increased

cytoplasmic GLUT4in db/db mice beyond that of+/db xmcQ(1.50±0.22 vs. 1.04±0.26 OD
units, p<0.01). The GLUT4 plasma membrane fraction in db/db mice was also 50% less
than +/<iZ> animals(0.262±0.09 vs. 0.502±0.06 OD units, p<0.05)but approximated that of

+/db mice with 500 ng T3/g BW dose(0.428±0.28 vs. 0.406±0.20 OD units, p>0.05). A

disproportionate depletion ofcytoplasmic GLUT4 m' db/db mice and a concomitant increase
in plasma membrane GLUT4 indicates that T3 regulates GLUT4 translocation from the
cytoplasm to the plasma membrane. Diabetic mice have reduced GLUT4 expression in the

plasma membrane whichlikely influences glucose uptake and contributes to hyperglycemia
in this model. However,thyroid hormone increases GLUT4 expression and translocation
in adipose tissue of

mice.

Ill

Total myocyte GLUT4 contents are similar in +/<iZ> and dh/db mice. T3 treatment

increased these quantities in both +/(i^(0.58±0.07 vs. 0.744±0.04 OD units, p<0.05)and
db/db (0.572±0.06 vs. 0.656±0.04 OD units, p<0.05) mice. The cytoplasmic GLUT4

quantity in vehicle-treated db/db mice was greater than +/db mice (0.326±0.05 vs.
0.268±0.05 OD units, p<0.05)while the membrane quantity in db/db mice was less than
+/db mice (0.246±0.03 vs. 0.312±0.06 OD units, p<0.05). Vehicle-treated db/db mice
possess total GLUT4 quantities equivalent to +/db mice, but have reduced plasma
membrane quantities which indicate disproportionate distributions of the GLUT4

transporter. However, T3 treatment(500 ng/g BW)m db/db mice,decreased cytoplasmic
GLUT4 content and increased plasma membrane fraction which suggests that T3 promotes
GLUT4 translocation.

T3-induced thermogenesis occurred in both +/(iZ> and db/db mice and the

temperature increase in db/db mice paralleled the appearance of GLUT4 in the plasma
membrane ofmyocytes. A 48% reduction in serum glucose concentrations was also found

in db/db xmce m response to T3 (592.0±126 vs. 334.9±62.9 mg glucose/dL, p<0.01).

Respiratory quotient(RQ) values indicate, however, a shift to fat catabolism with T3
treatment m db/db rmce(0.74±0.03). The apparent metabolic substrate in Tg-treated db/db
mice is not consistent with increased membrane-bound GLUT4 transporters facilitating
skeletal muscle glucose uptake which would lead to decreased serum glucose
concentrations. Enhamced glucose uptake by another tissue is suggested. This is the first

study to show that T3 restores GLUT4 translocation in
glucose transport defect underlying NIDDM.
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CHAPTER ONE: INTRODUCTION

Overview ofDiabetes Mellitus

Diabetes mellitus is a major health problem that appears in the written literature dating

back approximately two thousand years(Kahn and Weir 1994). According to the American
Diabetes Association, 16 million people are affected in the United States and an additional
500,000 to 700,000 individuals are diagnosed each year. It is the fourth leading cause of

death by disease among adults in the U.S. and it is expected that 178,000 individuals per
year will die from complications due to diabetes. It is a chronic disease that does not yet
have a cure.

Diabetes mellitus is a syndrome characterized by high concentrations ofserum glucose

(hyperglycemia)due to the inadequate control ofglucose levels. This results from the lack
of glucose uptake by the skeletal muscle, adipose tissue, and liver, and is also associated
with the inability to secrete or appropriately respond to insulin (Kahn and Weir 1994).
Because insulin is the normal hormonal signalfor cellular glucose uptake, an individual who

has this syndrome is in a chronic hyperglycemic state. The cause of diabetes is still

unknown,however both environmental and genetic factors have been implicated.
There are two general classifications ofdiabetes mellitus. Type I diabetes mellitus is

insulin-dependent diabetes mellitus(IDDM)and is most widely understood. It is the form
of diabetes most prevalent in children (juvenile onset).

IDDM individuals are

characteristically thin and have extremely low insulin levels. They produce minute quantities

or no insulin due to dysfunctional pancreatic P-cells(the cells which are responsible for

insulin production), defects in the insulin gene,and/or defects in the processing ofthe insulin

protein(Hadley 1992)which result in low functional levels ofinsulin. Because the lack of
insulin prevents glucose uptake by muscle and adipose tissue,these individuals have elevated
serum glucose concentrations and elevated ketone body levels due to increased fat

catabolism. Excess lipolytic activity occurs in order to provide the necessary energy from

fat stores in the absence ofglucose uptake(Kahn and Weir 1994). IDDM comprises 10%
of all diabetes mellitus cases and is the form of diabetes that is most familiar to people.
Further discussion ofthis form is not within the scope ofthis project.

Type n diabetes mellitus refers to non-insulin-dependent diabetes mellitus(NDDDM)
and it is the most common form ofdiabetes. NIDDM comprises90% ofall diabetes mellitus

cases(Kahn and Weir 1994), and it is the subject ofthis study. Itis typically adult-onset,
at first asymptomatic,and rather slow in developing. Individuals are characteristically obese
and produce excessive insulin, thus they are hyperinsulinemic. However, the tissues in

NDDDM individuals do not respond to insulin appropriately. Therefore, NIDDM individuals
are unable to effectively control glucose uptake because ofinsuhn resistance. NIDDM may

be caused by defects in the target cell such as a reduced number ofreceptors on the target
tissue surface(DeFronzo et al. 1992), post-receptor defects, altered function in the insulin

transduction mechanism due to reduced kinase activity (Stephens and Pilch 1995), or

cellular glucose transporter defects. All ofthese can cause hyporesponsiveness to insulin
(Hadley 1992)which would contribute to a hj^erglycemic state(DeFronzo et al. 1992;
Zorzano etal. 1996). Whereas nearly eighty-five percent ofthose individuals classified as

having NIDDM are also obese, the link between diabetes and obesity remains to be

determined(DeFronzo etal. 1992). It has been proposed that obesity may be diet-induced

(excessive intake ofcalories), may resultfrom decreased energy expenditure, or may be due
to altered lipid metabolism(Guerre-Millo 1996;Beck 1995); However,defective glucose

transport seems to be central to the hyperglycemic aspect ofthe syndrome. High serum

glucose levels persist since glucose is not properly handled by the insulin-hyporesponsive

skeletal muscle and adipose tissue, yet, glucose uptake by the liver continues to take place
and this substrate subsequently is converted to and stored as fat. This is also observed in

the adipocytes and may lead to obesity because the excess glucose taken up by adipocytes
can be converted into fat via lipogenesis and stored as triglycerides. Skeletal muscle from
NIDDM individuals, however,is not able to take Up glucose as readily by other mechanisms

therefore the insulin-responsive glucose transport mechanism warrants further investigation.

Diabetic Mouse Model

In order to study non-insulin-dependent diabetes mellitus, the C57BL/KsJ diabetic
{db/db)mouse is employed as the working animal model for this syndrome. The diabetes
mutation arose spontaneously in the C57BL/KsJ strain and the db gene is autosomal
recessive(Hummel et al. 1966; reviewed in Bray and York 1979). As in humans, this
mouse model displays high serum glucose concentrations and elevated insulin
concentrations, as well as age-dependent development of obesity(Hummel et al 1966;

reviewed in Bray and York 1979). This animal also displays decreased membrane-bound
GLUT4 in adipocytes(Gibbs et a/. 1995). Its tissues display insulin resistance and the

syndrome is the result ofa genetic defect. The mechanism for NIDDM in the db/db mouse

model yet remainsto be determined. Recently, Chua e/a/.(1996)reported that the

gene

on chromosome 4, which gives rise to the diabetes mutation in the C57BL/KsJ mouse,is

also the gerie that codesfor the leptin receptor. The "weight-reducing" hormone,leptin, is
said to be the protein product of the oh gene which is secreted by adipose tissue in

proportion to the fat content (Pelleymounter et at. 1995; Halaas et at 1995). Leptin
treatment in ob/ob mice has been shown to decrease body weight, decrease adiposity,
increase metabolic efficiency, and decrease voluntary feeding(Pelleymounter etal. 1995;

Halaas et at 1995). However,

mice have abnormally high serum leptin levels and

when treated with exogenous leptin do not respond to treatment(Pelleymounter etat 1995;

Halaas et at 1995)thus suggesting a defect in the OB-receptor, also known as the leptin
receptor(Chua et al. 1996). The receptor may represent one component ofthe afferent

signalling system (leptin action at the brain) but a defect at this level still does not
completely explain obesity in this animal model. The efferent signal to the target tissue
remains to be identified. This efferent signalling system may play a directive role in
specifying target tissue responses or in regulating tissue responsiveness to other hormones.

The G57BL/KsJ diabetic(db/db)mouse,a model for NIDDM and obesity, has been

shown to exhibit resistance to thyroid hormone(Tj). Obese-diabetic{dbldb)rmcQ display
excess adiposity, high serum T3 cqnceritrations, decreased serum;T4 concentrations(Fehn

et at 1988), low metabolic rates(spebific oxygen consumption rates)(Clark 1995), and
lower body temperatures (Hummel et at 1966) which suggest that these animals are

resistant to thyroid hormone. The animals are therefore considered to be fimctionally

"hypothyroid." It has been proposed that, as a result of being T3 resistant, the obese

diabetic mice accumulate fats due to decreased energy utilization and decreased mobilization

of fat stores (Fehn et al. 1988). Our laboratory has shown that treatment with

supraphysiological doses ofT3can overcome the targettissue resistance leading to enhanced
metabolic response, activation of fat mobilization from adipocytes, restored normal
metabolic rates, and increased thermogenesis. This indicates that the Tj-resistance exhibited

by the dh/db animals is not absolute but relatively refractory. Thus,the model allows for
the study ofT3 effects on physiological events, such as metabolism and glucose uptake.

Facilitative Glucose Transporters

Obesity is a common health problem in industrialized societies and it is characterized
by increased adipose tissue mass(Guerre-Millo 1996). Obesity may be caused by over

eating,lack ofphysical activity, or may be genetically determined. It is attributed to energy
imbalance, meaning that more calories are taken in as food than are expended to maintain
the basal metabolic rate or to engage in physical activity. In humans, obesity is strongly
associated with the development ofNIDDM(Considine et al. 1995), and was believed to

be caused by defects in the oh gene (Pelleymounter et al. 1995; Halaas et al. 1995).
However,recent studies have found no mutations in either the oh gene or the oh receptor

gene in humans,thusthey are not the cause ofobesity(Considine et al. 1996). Alternative

explanations are required to explain this pathology, and may include a defect in the glucose

transporter or in the vesicular translocation/trafficking mechanism. Although this defect
would not explain the entire basis for obesity,it might explain the redistribution ofglucose
away from the muscle to liver and adipose tissues. Since the skeletal muscle cannot take up

glucose efficiently in MDDM individuals, high serum glucose levels prevail which result in
glucose uptakethat predominantly occurs within the liver and adipose tissue. Glucose can
be taken up in adipose tissue by way ofglucose transporters that are expressed independent
ofinsulin action and in the liver via the GLUT2transporter(which will be discussed later).

Excess glucose taken up by these cells would then be converted into fats which would
contribute to increased adiposity.

Six proteins have been identified as being responsible for the facilitated diffusive
transport ofglucose down its concentration gradient across cell membranes and these have
been designated as facilitative glucose transporters: GLUTl,GLUT2,GLUT3,GLUT4,

GLUTS(Pessin and Bell 1992; Mueckler 1994), and GLUT?(Mueckler 1994), whereas

GLUT6(Stephens and Pilch 1995)has been identified as a pseudogene with no specific

function. Thistransport is driven exclusively bythe chemical gradient and not the hydrolysis
ofATP, nor is it coupled to either sodium or proton gradients.

GLUTl is expressed in the brain, kidney,colon, and red blood cells and is responsible
for basal glucose uptake. This transporter is constituitively expressed and has a Km value
ofapproximately 6.9 mM. This means that it has a high affinity for glucOse but it saturates

at physiological glucose concentrations. It is responsible for basal glucose transport and it
plays an important role in glucose transport across the blood brain barrier as well as other
barrier tissues(Mueckler 1994;Livingstone et al. 1996). GLUT2,a protein predominantly
expressed in the liver, is involved in hepatic uptake and release ofglucose and it apparently
functioiis as part of a glucose sensor. This transporter has a high Km for glucose

(approximately 13,2 mM),has alow affinity, and is not saturated vdthin normal physiologic

glucose conceritrations (Livingstone et til. 1996), Therefore^ it transports glucose in
quantities directly proportional to serum glucose concentrations. GLUTS is widely

distributed in human tissues(Mueckler1994)but is predominantly expressed iii the brain
and is responsible for constitutive neuronal glucoseuptake(Pessin and Bell 1992). GLUTS,

unlike the other transporters, has a very low Km for glucose(1.8 mM)and a high affinity
for glucose(Mueckler 1994)but it saturates atlow glucose levels; Thistransporter serves
as a fail-safe mechanism for glucose transport across the blood-brain-barrier in order to

ensure thatthe brain is constantly supplied with glucose,even during hypoglycemic states.
The GLUT4 glucose transporter is an insulin-regulatable glucose transporter that is found

in adipose tissue, cardiac muscle, and skeletal muscle. This transporter will be discussed in
more detail below. GLUTS is expressed in the jejunum. It has been characterized as being

responsible for intestinal absorption offructose and possibly other hexoses(Pessin and Bell
1992; Mueckler 1994). GLUT6 has been identified as a pseudogene having no specific
target tissue or function (Stephens and Pilch 1995). GLUT? transporter is expressed in
intracellular membranes of hepatocytes and possibly other gluconeogenic tissues. This

transporter allows glucose to diffuse freely from the endoplasmic reticulum of
gluconeogenic tissues in response to the action of glucose-6-phosphatase on glucose-6

phosphate(Mueckler 1994; Stephens and Pilch 1995). However,the actual significance of
this transporter's function remains unclear. The six different glucose transporter isoforms
have distinct characteristics and fiinctionsthat are dependent on the tissue in which they are
expressed. As such,the glucose transport rates ofthese glucose transporter isoforms are
characteristic ofthe function ofthe target tissue.

The GLUT4 glucose transporter protein, the focus ofthis project, is expressed in
skeletalmuscle,cardiac muscle^ and adipose tissue. It has a Km value ofapproximately 4.6

mM, it is positively responsive to insulin, and is involved in insulin-stimulated glucose

uptake(Pessin and Bell 1992, Stephens and Pilch 1995). This transporter is responsible for
a rapid increase in glucose uptake in response to increased serum insulin concentrations
(Mueckler 1994; Stephens and Pilch 1995). When stimulated by insulin, GLUT4
concentrations in the plasma membrane ofcells normally increase approximately 20-fold

(Pessin and Bell 1992). It has been reported that the plasma membrane GLUT4fraction in
adipose tissue(Stephens and PUch 1995)and skeletal muscle(Zorzano etal 1996)ofobese
NIDDM patients is reduced. This would have an overall impact on glycemic regulation

since glucose cannot be readily taken up by the target tissues. Thus, it would be of
importance to gain a better understanding of the GLUT4 regulatory mechanisms and
expression in NIDDM. Since NIDDM individuals have impaired glucose uptake, alterations
in the structure,function, or regulation ofthe glucose transporters, specifically GLUT4,are

good candidate mechanisms for transport defects associated with this syndrome. The

GLUT4 glucose transporter is an integral membrane component found in insulin responsive
tissues. Little is known ofthe regulatory mechanisms which control GLUT4 transporter
expression and distribution in the skeletal muscle and adipose tissue. This will be the central
focus ofthe study.

GLUT4 Vesicular Trafficking

The GLUT4 transporter facilitates glucose uptake across the plasma membrane

between the serum and cell cytoplasm and normally increases in number with increased

insulin concentrations. The GLUT4 transporter protein is processed and translocated like
other proteins within the cell by the following mechanisms. Proteins are synthesized at the

endoplasmic reticulum and move toward the Golgi complex for fiarther processing and
modification within a spike-coated vesicle as part ofa process known as vesicular trafficking

(Morris and Frizzell 1994; Gauter et al. 1994). The vesicle fuses with the c/5-face ofthe

Golgi complex,and subsequently buds fi-om the organelle. The vesicle then fuses with the
medial-incG ofthe Golgi complex and after further modification and processing, the vesicle
buds. The budded vesicle then approaches and fuses with the trans-iaco. of the Golgi

complex. Within the trcms4acQ ofthe Golgi complex,the vesicle is labelled with mannose
6-phosphate receptors and these identify the vesicle as one which will reside in the

cytoplasm. The vesicle is removed from the secretory pathway and is localized in a region

of the Golgi complex where the vesicle becomes clathrin-coated. Such processing is
characteristic oflysosomal vesicles. However,ifthe vesicle is to be secreted, it remains
uncoated, as is the case with GLUT4-containing vesicles (Stephens and Pilch 1995).

Subsequently,these vesicles with their protein contents are then transported towards the

plasma membrane (translocation) where the vesicles will dock and fuse with the plasma

membrane and incorporate their contents into the membrane as integral transmettibrane
proteins(Appendix 1).
Vesicles are believed to be transported through the cytoplasm driven by kinesin along
microtubules(Morris and Frizzell 1994). A vesicle attaches to kinesin, a molecule that

serves asthe motor in the translocation process,and this molecule is activated by Ca^^. The

intracellular activity ofkinesin is regulated by the influx ofCa^^ into the cell or Ca^^ release
from the endoplasmic reticulum(or the sarcoplasmic reticulum ifthe process is occurring
within the skeletal muscle). This propOrtedly stimulates movement of kinesin along a
microtubule, which transports the vesicle towardsthe surface ofthe cell(Morris and Frizzell

1994). The vesicle then comes in contact with various docking proteins at the membrane
surface. These proteins enable the vesicle to dock and fuse thereby integrating into the
membrane the vesicular protein components(Appendix 2).
Vesicular translocation, docking, and fusion with the plasma membrane involve a

series of steps regulated by several key proteins. The vesicle membrane contains the

proteins synaptobrevin and synaptotagmin(12kDa and 65 kDa integral membrane proteins,
respectively). These form a 7S docking complex with a 25 kDa protein SNAP-25

(Synaptosomal Associated Protein-25), and syntaxin(32 kDa),both ofwhich are located
in the plasma membrane ofthe cell (Scheller 1995; Bark and Wilson 1994). As a-snap
(Soluble NSF Associated Protein) associates with the 7S complex synaptotagmin is

dislodged. A 20S complex is formed when cytoplasmic NSF(N-ethylmaleimide-Sensitive
Factor)associates with a-snap on the7S complex. NSF protein binds ATP and, as a result
ofATP hydrolysis, NSF and a-stiap dissociate from the 20S complex. Syntaxin, which is

tightly associated with the integral membrane proteins Neurexins and Ca^^ channel proteins,
is thus exposed and is able to associate with synaptotagmin on the vesicle. The association

stimulates a conformational shift of the associated complex causing an influx of Ca^^.

Synaptotagmin,which is sensitive to Ca^^ binds

and this causes another conformational

shift in the associated proteins. This shift subsequently causes SNAP-25 and the syntaxin

10

synaptotagmin fijsion complex to separate along the cell membrane thereby creating a "gap"
in the cell membrane which enables the proteins from the vesicle to become embedded
within the membrane(Bark and Wilson 1994; Scheller 1995). Stephens and Pilch(1995)
state that the docking-fusion mechanism ofGLUT4-containing vesicles is similar to that of

the neurotransmitter secretion model(as described above), differing only in a few docking

proteins that are specific for GLUT4. Although the GLUT4 translocation mechanism may
be a point for potential defects within NIDDM, non-functional docking proteins on the
vesicle or plasma membrane as well as lack offusion and integration ofvesicular contents
are also potential candidates. The current study will address translocation and docking of
the GLUT4 glucose transporters in tissues from normal and obese-NIDDM subjects.

GLUT4 Studies

Studies in transgenic mice,into which the fiinctional GLUT4 gene has been transfected

from humans,and diabetic animal models have consistently shown that insulin increases the
quantity ofGLUT4 at the plasma membrane ofadipose tissue and leads to a concomitant
decrease in cytoplasmic GLUT4 quantity. Zorzano et al. (1996) reported that insulin
treatment similarly caused the GLUT4 quantity in adipose tissue and skeletal muscle to
increase at the plasma membrane and decrease in the cytoplasm. Other studies using

transgenic animals showed that tissues from transgenic animals (skeletal muscle and/or
adipose tissue) had significantly greater GLUT4 present in the plasma membrane in
comparison to their non-transgenic counterparts(Brozinick et al. 1996; Gibbs et al. 1995;
Olson and Pessin 1995; and Hansen et al. 1995). Upon insulin stimulation, there was a

11

more dramatic increase in membrane bound GLUT4 transporter quantity in the transgenic

mice in comparison to non-transgenic mice. There was a concomitant decrease in the

GLUT4 quantity in the cytoplasm indicating that GLUT4-containing vesicles translocated
from the cytoplasm to the plasma membrane. Gibbs etal.(1995)utilized a hGLUT4 db/dh

transgenic mouse that carries a functional human GLUT4 gene which leads to GLUT4
transporter overexpression. This study showed that the glucose transport defect(reduced
plasma membrane GLUT4 content)in transgenicdb/db mice could be compensated for by
inducing extra GLUT4transporters which correctfor insulin resistance. This indicated that
insulin insensitivity in this model ma^y be at the level ofvesicular translocation, doclting, or

fusion, since upregulation oftranspofter expression could overcome the glucose transport
defect. The transgenic db/db mice showed a marked decrease in hyperglycemia due to
increased glucose transport via the GLUT4 glucose transporter in Comparison to the non

transgenic

mice. The targettissues, skeletal muscle and adipose tissue,in these mice

are resistant to insulin's action on GLUT4induction and/or translocation which suggests that
GLUT4 translocation may be regulated by another factor or another hormone since

translocation took place in the absence ofinsulin signalling. The translocation defect can
be compensated by GLUT4 overexpression but it can also be potentially corrected by the
direct action ofanother hormone other than insulin on elements involved in the translocation

process. If this is the case, an increased number of GLUT4 transporters at the plasma
membrane could facilitate increased glucose uptake and could improve the glycemic status
ofthe MDDM subjects. Since the process ofGLUT4 transporter protein expression in the

plasma membrane and translocation is insulin-responsive, the regulation ofthe GLUT4
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transporter is a likely candidate for altered function in non-insulin-dependent diabetes
mellitus and warrants further investigation.

NIDDM and Obesity

Several factors that may contribute to the onset of obesity include overeating,
metabolic defects, hypothalamic disorders, increases in carbohydrate,fat, or protein intake,
and decreased physical activity(Beck 1995; Guerre-Millo 1996). Adiposity can manifest
in general categories ofpresentation which reflect either cellular hypertrophy or hyperplasia,

or both. Enlargement ofthe adipocytes may be due to an increase in cell volume which is
associated with excessive fat storage and is characteristic ofhypertrophy. Alternatively, an
increase in the overall number ofadipocytes is characteristic ofhyperplasia which results

from excessive mitotic divisions(Hadley 1992). Adipocytes within adipose tissue serve as
an efficient energy repository by housing fat droplets which contain two times the amount
of potential energy per unit of weight compared to either proteins or carbohydrates.
However, the prevalence of obesity in relationship to non-insulin-dependent diabetes
mellitus is not yet understood.

Eighty-five percent of individuals with NIDDM are also characteristically obese.
Studies have reported increased adipocyte volumes and decreased membrane-bound GLUT4

in adipocytes of NIDDM subjects (Fabres-Machado and Saito 1995) and oht^Q-db/dh
animals (Estrada unpublished observations). The adipocytes in subjects with NIDDM
generally increase in lipid content, cell number, and/or cell size (Bjomtorp 1987), thus
accounting for the obesity associated with the syndrome. Obesity is also associated with

13.
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insulin resistance such that insulin-sensitive tissues(primarily skeletal muscle and adipose

tissue) are not able to respond to insulin appropriately and thus have impaired glucose
uptake. Since the majority of NIDDM individuals are obese; perhaps obesity is also

associated with alterations in facilitated glucose transport via defective GLUT4 transporter
function. Onset ofobesity in NIDDM subjects, including the db/db mowse,is associated

with decreases in both specific Ojconsumption, as well as total metabolic rate(Glark 1995;
Jequier 1987). These responses are also observed in a phenotypically-related model, the
mouse(Boissonneault et al. 1978; Oh and Kaplan 1994). The reduced metabolism

ofNIDDM subjects apparently conserves energy, which is then stored causing increased

adiposity. The mechanism that results in a decreased metabolic rate and increased adiposity
(pofentiallyleading to the onset ofNIDDM)however, still reniains undetermined.

Glucoregulatorv and Thyroid Hormones
There are many hormonal signals that are involved in regulating glycemic status, such

as glucagon,insulin, and the catecholamines(specifically epinephrine). Glucagon stimulates
the release ofglucose fi'om the liver via glycogenolysis (in order to maintain short-term
levels of blood glucOse in a well-fed animal) or gluconeogqnesis (in order to maintain

glucose levels under prolonged fasting or exercise periods). Insulin is secreted by the Islets

ofLangerhansin the pancreas, specifically the P-cells,in response to elevated serum glucose
levels. Insulin enhances glucose uptake by the hepatocytes, myocytes, and adipocytes where
it is metabolized, stored as glycogen, or used as a substrate to synthesize proteins or fats.

Epinephrine, however,inhibits glucose uptake by adipocytes during periods ofstress. This
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ensures that dtiring times ofsuch activity, glucose is taken up niore readily by the liver,
skeletal muscle, or brain instead ofbeing stored away. Thus, serum glucose levels are not

regulated solely by one hormone but rather regulation involves the action of multiple
hormones that are dependent on the physiological status ofthe individual.

While a variety of causative agents(mentioned above) have been proposed in the
regulation ofthe glycemic status within an individual, another hormone,triiodothyronine

(T3), may be indirectly involved in regulating the glucose levels. Thyroid hormone plays a
role in the regulation ofgrowth,development, and metabolism(Glass and Holloway 1990).
Thyroid hormone controls the baseline metabolic rate ofanimals and is also permissive to
the action of other hormones such as insulin (Hadley 1992). This means that thyroid

hormone action is required for insulin to act on the insulin-sensitive tissues and ehcit a

response. However, NIDDM individuals are resistant to insulin and their tissues cannot

adequately take up glucose. Thus,thyroid hormone's permissive action to insulin should
increase insulin sensitivity at the target tissues and thyroid hormone should be accounted for

as a potential mediator in NIDDM.
Thyroid hormone is regulated at several levels and by several tissues.

The

hypothalamus regulates pituitary gland secretion ofthyroid stimulation hormone(TSH)via
thyrotropin releasing-hormone(TRH). The pituitary gland produces and releases Thyroid-

Stimulating Hormone (TSH) which, in turn, stimulates the thyroid gland to produce
thyroxine(T4),the metabolically inactive form ofthyroid hormone. T4 is converted to the
metabolically active triiodothyronine(T3)via 5'-monodeiodinase in the liver and kidney. T3

is responsible for regulating metabolic activity within most cells(Oppenheimer 1994). It

acts by binding to nuclear receptors located On the DNA where it forms dimeric hormone-

receptor complexes which are responsible for regulating gene transcription and the
expression ofgene products. This hormone is responsible for regulating metabolism at the
tissue level. It potentiates lipogenesis(fat synthesis)in the liver by inducing the synthesis

of hepatic lipogenic enzymes, lipolysis (fat catabolism) in adipose tissue by inducing the
lipolytic enzymes (Glass and Holloway 1990), and thermogenesis(heat production) in
skeletal muscle by inducing Na^/K^-ATPase (Glass and Holloway 1990; Oppenheimer

1994). It is, therefore, an important regulator ofoverall energy balance.
The db/db mice are resistant to thyroid hormone(T3) which means that the target

tissues are relatively unresponsive to the action ofthyroid hormone. While these animals

have high serum T3 levels which make them technically hyperthyroid,they are functionally
hypothyroid since they are hyporesponsive to T3. The target tissue resistance can be
overcome with supraphysiological doses which results in an enhanced metabolic response,
activation offat mobilization from adipocytes, restoration to normal metabolic rates, and
increased thermogenesis(Clark 1995;Estrada unpublished results). These are responses

that are potentially linked to glucose transport since an increase in glucose uptake can
provide the substrate to be utilized in metabolic and thermogenic processes. Since db/db
animals are T3resistant,thyroid hormone cannot elicit its permissive action to insulin within
the animal's tissues. This may contribute to the insulin resistance characteristically seen in
NIDDM subjects. Thus,the insulin-responsive GLUT4 transporter is a likely candidate for

thyroid hormone regulation.
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Thyroid hormone has been reported to regulate GLUT4 expression in adipose tissue
(Matthei et al. 1995) and skeletal muscle (Weinstein et al. 1994; Weinstein et al. 1991;

Casla et al. 1990). A pilot study (Estrada unpublished results) on the effect of T3 on
GLUT4 expression has also shown that T3 regulates the GLUT4 transporter in the db/db
mouse. Thyroid hormone treatment regulates the redistribution (translocation) of the
GLUT4-containing vesicles within the cjhoplasm of adipocytes towards the plasma

membrane and may regulate the docking-fusion mechanism(Estrada unpublished results).
However, no pubhshed information exists on the role of thyroid hormone on GLUT4
glucose transporter regulation in

mice.

Proposed Effect ofThyroid Hormone on GLUT4 expression
In the present study,the effect ofT3 on GLUT4 glucose transporter expression will
be assessed in lean C57BL/KsJ +/db and obese-diabetic C57BL/KsJ db/db mice. This will

be done by comparing the content ofGLUT4 transporters in adipose tissue and skeletal
muscle from vehicle-treated normal and obese-diabetic mice with the tissues obtained from

normal and diabetic mice treated with exogenous T3 for nine days. Because adipose tissue
and skeletal muscle in db/db mice are resistant to insulin(reviewed in Bray and York 1979;

Hummeletal. 1966),the quantity ofGLUT4 present in the plasma membrane is expected

to be below normal since insulin action is needed to induce GLUT4 mRNA expression
(Sinha etal. 1991). The quantity ofGLUT4 in the cytoplasmic fraction(the result ofgene
transcription and translation)and plasma membrane fraction(the result ofprotein transport,
docking, and fusion) wall be evaluated.
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The target tissues in individuals with NIDDM are resistant to insulin leading to

impaired glucose uptake and hyperglycemia. In insulin- and Tj-resistant dh/dh mice,the
insulin response may be restored via overcoming the thyroid hormone resistance with
supraphysiological doses of Tj. This could then result in regulation of the GLUT4
transporter via Tj treatment. Under the assumption that T3 may play a role in GLUT4
expression and/or vesicular trafficking, treatment with thyroid hormone should increase
GLUT4 transcription. This, in turn, should lead to increased translation ofthe GLUT4

transporter protein. Subsequently, an increase in GLUT4-containing vesicles should be
observed, as well as increased vesicle fusion with the plasma membrane ofadipocytes and
myocytes ofdb/db mice.

There are five potential sites of action for regulation of the GLUT4 glucose
transporter ifthe GLUT4 quantity at the plasma membrane increases in response to T3
treatment. 1)T3 may regulate gene expression at the transcriptional level because thyroid
hormone has nuclear receptors on the DNA. This could potentially regulate gene
transcription of mRNA for the GLUT4 transporter or various elements involved in the

GLUT4 trafficking mechanism;2)This event could alternatively lead to increased translation

ofthe GLUT4transporter protein by enhancing translational efficiency; 3)or by stabilizing
the GLUT4 transporter mRNA;4)Triiodothyronine might also increase incorporation of

GLUT4 transporters into vesicles via regulation ofprocessing occurring within the Golgi
complex; 5) Thyroid hormones (T^ in this case) have been shown to regulate actin
polymerization and this may play a role in GLUT4 vesicle transport and fusion with the

plasma membrane(Leonard 1997). An assessment oftotal GLUT4 protein expression and

.
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cellular distribution was performed in a pilot project to narrow these possibilities.

The pilot project of GLUT4 expression in adipocytes was conducted using an
experimental design similar to that proposed for this study except that the tissues were not
homogenized fresh but rather after storage at -20°C. Normal{+/db)and diabetic(db/db)
mice were treated with exogenous Tj(0 ng/g BW or 500 ng/g BW)for ten days and each

treatment group consisted offive animals. Animals were euthanized on day 10 ofstudy with

CO2. Adipose tissue was extracted and homogenized in order to separate the cytoplasmic
and plasma membrane fractions. Homogenates(0.5 pg protein/100 pi)were loaded onto
nitrocellulose paper using a dot blot apparatus for immunodetection of the GLUT4

transporter. A commercial polyClOnal GLUT4 antibody (rabbit-anti-insulin regulatable
glucose transporter, East Acres Biologicals)was used to identify the GLUT4 transporter
and was visualized using chemilumenescence detection(AmershamRPN 2108). GLUT4
transporters were quantified using a Bio-Rad video densitomter and data were reported as
OD units.

Total GLUT4 expression in +/db mice increa.sed with T3 treatment which suggested
GLUT4induction in response to T3. Jndb/db tmce,total GLUT4 expression decreased with

T3 treatment(Table 1). The quantity ofGLUT4 in the cjdoplasm of+/db mice increased
with T3 treatment (0.158±0.07 vs 0.196±0.05, repectively; p<0.05) whereas in db/db
animals,the cytoplasmic quantity decreased in response to T3(0.284±0.04 vs. 0.178±0.07,

respectively; p<0 05). The quantity of membrane-bound GLUT4 transporter in +/db
animals did not change with T3treatment(0il68±0.05 vs. 0.170±0.02, respectively; p>0.05)
which suggested Tj had no eflfect and represented^ normal turnover. However,in db/db
/// 19 ■ ■

TABLE 1. OD readings ofadipocyte cytoplasmic and membrane-bound GLUT4 proteins
in vehicle-treated(0 ng Tj/g B\\0 and Tj-treated(500 ng/gBW)normal(+/db)and diabetic
mice. (Valuesi SEM,n=5).
Phenotype/Treatment Group Cytoplasm

Membrane-Bound

Total GLUT4

+/0

0.158 ±0.068

0.168 ±0.053

0.326±0.16

db/G

0.284 ±0.040

0.062 ±0.058

0.346±0.13

+/500

0.196±0.047

0.170 ±0.020

0.366±0.23

db/500

0.178 ±0.071

0.090 ±0.024

0.268 ±0.12

animals, the GLUT4 quantity increased at the plasma membrane with T3 as a concomitant

decrease in cytoplasmic GLUT4 was observed. These were indications that GLUT4
transporters were being redistributed from the cytoplasm to the plasma membrane in db/db
animals The intent ofthe pilot study was to determine ifthyroid hormone altered GLUT4

transporter expression in db/db mice. Based on this study, it was concluded that thyroid
hormone was not likely to be affecting GLUT4 transporter mRNA transcription in the
insulin-resistant db/db mice because a pool ofcytoplasmic GLUT4 transporters existed in
vehicle-treated

mice.

Adipocjdes were evaluated in the pilot study as a reference point so as to provide a
framework on the role ofthyroid hormone in regulating GLUT4 expression. This could

then be used to formulate hypotheses in reference to the action pfthyroid hormone on
GLUT4 expression in another insulin responsive tissue, skeletal muscle, and the impact it
would have on metabolic responses observed in other studies. In the current study, GLUT4

protein expression and subcellular distributions will be assessed in normal and diabeticmice
to see if T3 influences GLUT4 transporter trafficking phenomena. This will be done by

quantifying the total GLUT4transporter present in the cell cytoplasm and plasma membrane
20..

under various thyroid hormone treatments to determine ifGLUT4 transporter translocation

from the cytoplasm to the plashia membrane occurs. The total GLUT4 quantity will be
indicative ofthe induction process and the distribution ofthe cytoplasmic and membrane-

bound GLUT4 fractions will be representative of the trafficking mechanism. The
implication ofincreased numbers ofmembrane-bound GLUT4 transporters is that it would
allow for increased glucose transport into skeletal muscle and adipose tissue. This would

then be utilized by the skeletal muscle as a fuel source for thermogenesis. Ifan increase in
heat production does occur, the body temperatures oidb/db mice should increase and an

increase in oxygen consumption should be observed.
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CHAPTER TWO: MATERIALS AND METHODS

Animals and Tissues

C57BL/KsJ heterozygous normal(+/db)and homozygous diabetic(dbldb)mice were
obtained from Jackson Laboratories(Bar Harbor, Maine). The animals were housed at

approximately 23°C under a 14:10 light;dark cycle. Lights were on from 6 am until 8 pm

daily, and five animals were housed per cage in 11" long X 7" wide X 5" tall plastic cages
with wood chip bedding and white tissue. Water and Teklab 4% rodent chow were
available ad libitum.

Female +/db zxA dbldb mice, 8-10 week old, were preconditioned 1 week prior to

study by handhng, exposure to metabolic chambers, and being subjected to temperature

reading procedures. After preconditioning, animals received daily intraperitoneal injections
ofthyroid hormone(L-3,5,3'triiodothyronine; Sigma #T2877)in doses of0, 100,200, and
500 ng Tj/g body weight for nine consecutive days(Kalousek 1986; Clark 1995). T3 was

prepared daily using 100 pg/mlin 0.5 mM NaOH and was protected from light via wrapping

the injection bottle with aluminum foil. The control animals received intraperitoneal
injections of0.5 mM NaOH in proportional volumes(2 gl/g body weight). Each treatment
group consisted of five +/<i& and five dbidb animals. Injections were administered between
8 am and 10 am after daily body weights, metabolic readings, and body temperatures were
recorded. On day 10, animals were euthanized by COj. Blood was collected from each
animal by cardiac puncture. Tissues(adipose tissue and skeletal muscle)were excised and

processed(see below)to obtain homogenates for GLUT4 analysis.
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Metabolic Rate Determinations and Temperature Studies

Oxygen consumption and carbon dioxide production rates ofthe mice were measured

for 3 minutes each day for 10 days using an Ametek S-3A/n Oxygen Analyzer and an
Ametek CD-3A Carbon Dioxide Analyzer. An open flow system using room air was

utilized and was calibrated daily prior to use with gases ofknown concentrations. Readings

were taken at a constant flow rate of 400 ml per minute (as determined by Gilmont
Flowmeter, modelD-665)in order to determine relative metabolic responses. Daily rectal
body temperatures for normal and diabetic mice were recorded using a temperature probe

(Sensortek Thermocouple, model BAT-12)and radiant heat was measured on days 7-10

with a Microprocessor Thermometer(Type J-K-T Thermocouple, model HH21). Data are
reported as respiratory quotient(RQ,ml COJ ml Oj)and temperature("C).

GLUT4 Fractionation Studies

Omental adipose tissue (0.25 g)and gastrocnemius skeletal muscle (0.05 g) were
excised and homogenized in 1 ml ofSTM/PMSF buffer(0.32M sucrose, 3mM MgCl2, and
0.5% Tween 20,0.IM Phenylmethylsulfonyl Fluoride)using a motorized glass homogenizer

at room temperature for 45 seconds. Homogenates were centrifuged at 14,000 g for 5
minutes at 4°C(Herman et al. 1994)to produce a supernatant containing the cytoplasmic

vesicles and a pellet containing the plasma membrane with docked vesicles. The supernatant
(approximately 1 ml)was transferred to a fresh microcentrifuge tube. In order to splubilize

membrane-bound proteins in the pellet(docked vesicles and fused transporters), 5 ml of
STM buffer was added to the pellet and this was subsequently sonicated(Bronwill Biosonik
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model)for 1 minute at 80% power and the resultant homogenate centrifuged at 14,000 g
for 5 minutes at4°C(Herman

a/. 1994)to remove remnants ofthe plasma membrane and

vesicles. The homogenates were stored at -20°C until analyzed.

GLUT4 Quantification

The Coomassie Brilliant blue method(Bradford 1976; Matthaei et al. 1995)using a

Bovine Serum Albumin(BSA,Sigma#A7906)standard was utilized to quantify the protein
content ofthe supernatants and the pellets.

A 100 pi aliquot of homogenate (approximately 0.313 pg) was subjected to dot

blotting and immunodetection using a polyclonal antibody against GLUT4(Rabbit AntiInsulin Regulatable Glucose Transporter,East Acres Biologicals)(Burcelin 1993). A 96
well microtiter plate was prepared that contained various dilutions ofthe supernatant and

pellet samples resulting in 0.313 pg total protein/100 pi for dot blot procedures. A 100 pi
aliquot ofeach sample was loaded into individual wells ofthe dot blot manifold. Samples
were loaded on to the nitrocellulose membrane(0.2 pm,Protran #BA83)by vacuum and
each well was rinsed twice with 100 pi TBS(20 mM Tris, 500 mM NaCl, and 0.0001%

merthiolate, pH 7.5). The nitrocellulose paper was blocked with BLOTTO(5% Carnation
non-fat milk in TBS, Tris-buffered Saline) for 30 minutes at room temperature, while

shaking. A 1:10,000 dilution ofGLUT4 polyclonal antibody(5 pi in 50 ml BLOTTO)was
added to the blot which was inCubated in a covered polyethylene dish while shaking

overnight at room temperature. This was followed with 3 BLOTTO rinses for 10 minutes
each at room temperature. After the third rinse, 10 pi of the secondary antibody
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(biotinylated goat-anti-rabbit IgG, Signia#B-9642)in 25 ml BLOTTO(a 1:2500 dilution)

was added and incubated at room temperature for 3 hours while shaking. Following this
incubation, blots were rinsed in TBS 3 times at room temperature for 10 minutes each.

Twenty microliters ofavidin-horse radish peroxidase(AV-HRP,Bio-Rad)in 20 ml TBS(a

1:10,000 dilution)was added and incubated at room temperature for 1 hour while shaking,

followed by 3 rinses in TBS. The blot was then subjected to chemiluminescence detection
(Amersham #RPN2108)using Kodak RP X-Omat fihn. The GLUT4 fluorograms were
quantified using a Bio-Rad model 620 video densitometer(Herman et al. 1994). GLUT4
protein data are reported as Optical Density(O.D.)uruts.

Serum Glucose Determination

Serum glucose concentrations were determined with a commercial glucose assay kit
(Sigma#115A)using 0.4 pi ofserum fi^om each animal. This assay produces a colorimetric
response measured at 520 nm using a microplate reader(BIO-TEK instruments. Model EL

312e)that is proportionalto the serum glucose concentrations. Data are reported as mg/dL.

Statistical Analysis

Data represeneting body mass,temperature, metabolic studies, GLUT4 transporter

protein characterization, and the serum glucose assay were subjected to multifactorial
analysis of variance(ANOVA)and Duncan's Multiple Range Test(Mason et al. 1989).
Data are reported as means ± SEM and n=5 in all cases. A single asterisk(*) denotes

significance at p<0.05 and two asterisks(**)denqte significance at p<0.01.
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CHAPTER THREE: RESULTS

GLUT4 Fractionation Characterization

The effect of T3 on GLUT4 transporter expression in +/db and db/db mice was

investigated by comparirig the totai GLUT4transporter expression, cellular distribution of

and the fraction ofGLUT4tr^porters associated with the plasnia membrane in adipocytes
-treated animals. Tissue homegenates
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Figure 1. Total GLUT4 transporter Content in adipocytes ofnormal(+/<®)and diabetic
(db/db)mice treated with T3(0, 100,200,and 500 rig/g BW). Comparisons are between

phenotypes at thegiyen dose(Values are± Sem,n=5).

mice in response to T3(Figure 1).
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The total GLUT4 quantity in adipocytes of+/db animals that were vehicle-treated or treated
withTOO or 200 ng Tg/g BW were not altered. In the mice that received 500 ng Tj/g BW

dose, the total GLUT4 quantity decreased in comparison to the vehicle-treated animals
(1.758±0.15 vs. 1.99±0.19 OD units, respectively; p<0.01). These data suggest that within

physiological concentrations T3 treatment does not alter the number of GLUT4 glucose
transporters and apparently does not regulate induction. In dh/db mice,the total GLUT4
quantity in adipocytes ofvehicle-treated animals was approximately 50% less than normal,
vehicle-treated animals (0.886±0.15 vs. 1.99±0.19 OD units, respectively; p<0.01).

However,increasing doses ofT3 increased total GLUT4 transporter expression in db/db

mice(Figure 1)with maximal expression occurring at 500 ng T3/g BW. At this dose,the
total quantity of GLUT4 transporters was greater than vehicle-treated db/db mice

(1.928±0.11 vs. 0.886±0.15 OD units, respectively; p<0.01)and approached the quantity
observed in vehicle-treated, +/db animals(1.92840.11 vs. 1.99±0.19 OD units, respectively;

p>0.01). This suggests that GLUT4 transporter induction occurred in response to T3
treatment which resulted in normalization oftotal GLUT4 transporter quantities.
The quantity ofGLUT4 transporters in the cytoplasm ofadipocytes was assessed in
+/db and db/db mice(Figure 2). The baseline expression ofGLUT4 transporter protein in
the cytoplasm ofadipocytes ofvehicle-treated, +/db animals was 1.488=1=0.18 OD units and
no change was observed at 100 and 200 ng T3/g BW doses. Treatment with 500 ng T3/g

BW, however, caused a decrease in quantity (1.488=1=0.18 vs. 1.04=1=0.13 OD units,
respectively; p<0.01). The basehne quantity of cytoplasmic GLUT4 transporters in
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Figure 2. Gytbplasmie GLUT4 transporter content in adipocytes of nbrinal (+4/5) and
diabetic {db/db) mice treated with T, (0, 100, 200, and 500 ng/g BW). Comparisons are
between phenotypes at the given dose (Values are ± SEM, n-5).
adipocytes ofdb/db mice was approximately 50% less than normal, vehicle-treated animals
(0.624±0.11 vs. 1.488±0.18 OD units, respectively; p<0.01). In diabetic mice, the

^0.

dose of 200 ng Tj/g BW (0.288+0.10 OD units; p<0.05) in comparison to the vehicletreated cU)/db mice. However, the quantity of GLUT4 transporter within the cytoplasm at

to the vehicle-treated, db/db animals (1.55+0.22 vs. 0.624+0.22 OD units, respectively;

p<0.01), and approached values of normal, vehicle-treated animals (1.50+0.22 vs.
1.488+0.36, respectively; p>0.05). These data suggest that T3 treatment plays a role in
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Figure 3. GLUT4 quantity associated with plasma membrane of adipocytes of normal
{+/db) and diabetic (db/db) mice treated with T3 (0, 100, 200, and 500 ng/g BW).
Comparisons are between phenotypes at the given dose(Values are ± SEM,n=5).
The baseline GLUT4 quantity associated with the plasma membrane ofadipocytes in
vehicle-treated +/db mice,shown in Figure 3, was approximately 0.502±0.03 OD units; T3
did not change this value at any dose(0.470±0.01, 0.600±0.17 OD units, and 0.406±0.10

OD units respectively, p>0.05). These values represent the normal expression levels of

GLUT4 transporters at the plasma membrane. The baseline expression ofthe GLUT4

transporters associated with the plasma membrane ofadipocytes from vehicle-treated, db/db
mice was approximately 50% less than normal mice(0.262±0.05 vs. 0.502±0.03 OD units,

respectively; p<0.05). The replacement dose of100 ng T3/g BW restored membrane-bound
GLUT4 levels to those ofnormal, vehicle-treated animals(0.474±0.01 vs. 0.502±0.03 OD

units, respectively; p>0.05). At the hyperthyroid dose(200 ng Tg/g BW),the quantity of
GLUT4 transporter associated with the plasma membrane increased dramatically in
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comparison to vehicle-treated

mice (0.262±0.05 vs. 0.986±0.55 OD units,

respectively; p<0.05) and exceeded that of +/£ZZ' mice treated with the same dose
(0.986±0.28 vs. 0.600±0.17,respectively; p<0.05). However,the GLUT4 quantity in db/dh
mice at the supraphysiological dose was indistinguishable from that of normal animals

(0.428±0.14 vs.0.406±0.IG OD units,respectively; p>0.05). The membrane-bound GLUT4
quantity of db/db mice increased with the replacement and hyperthyroid doses in

conjunction with decreases in cytoplasmic GLUT4 transporter content. This redistribution
suggests that Tj may play an important role in supporting vesicular translocation.
The proportion oftotal GLUT4 transporters associated with the plasma membrane
was assessed in adipocytes of+/<iZ» md db/db mice in order to determine whether T3 might

play a role in regulating GLUT4 transporter cellular distributions and are reported as a
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Figure 4. Fraction of GLUT4 transporters associated with plasma membrane of adipocytes
ofnormal (+/db) and diabetic (db/db) mice treated with T3 (0, 100, 200, and 500 ng/g BW).
Comparisons are between phendtypes at the giveh dose (Values are ± SEM, n=5).
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percentage (Figure 4). The plasma membranes of vehicle-treated +/db mice contained
26±3% ofthe total GLUT4 quantity. The GLUT4 transporter percentage associated with
the membrane remained unchanged at all doses of Tjin comparison to vehicle-treated
animals. These data suggest that the distribution of GLUT4 transporters between the

cytoplasmic fraction and plasma membrane is not under control by Tj, at least with respect
to physiological doses present in +/db animals. In vehicle-treated db/db mice, the
percentage ofGLUT4transporters associated with the plasma membrane ofadipocytes was
29.5±1%(Figure 4). In mice that received 100 ng Tj/g BW dose,the percentage ofGLUT4
increased approximately 2-fold in comparison to vehicle-treated db/db animals(59±2% vs.
29.5±1% respectively, p<0.01)and subsequently increased again with 200 ng Tj/g BW to

76±7%(p<0.01). With 500 ng Tj/g BW,the percentage ofGLUT4 associated with the
membrane significantly decreased in comparison to db/db mice receiving hyperthyroid doses

(21.6±6% vs. 76±7%,respectively; p<0.01),and approximate values observed in +/db mice
(21.6±6% vs.26±3%,respectively; p>0.05). In vehicle-treated animals, the fraction oftotal
GLUT4 associated with the plasma membrane is equal in both +/db and db/db mice
suggesting a proportionate distribution. T3 treatment does not alter GLUT4 redistribution
in +/db animals. But,in db/db mice which are T3 resistant and functionally hypothyroid, T3

stimulated a redistribution with proportionately more GLUT4 residing in the plasma
membrane. This represents the basal ejEFect ofT3on GLUT4 trafficking htcmst db/db mice
are "normalized" at supraphysiological T3 doses. These data show that T3 treatment

increases the percentage ofGLUT4 transporters associated with the plasma membrane of

adipocytes in db/db mice. Thus, T3 plays a role in GLUT4 transporter translocation.
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Figure 5. Total GLUT4 transporter content in myocytes ofnormal {+/db)and diabetic
{db/db) mice treated with Tj(0, 100, 200,and 500 ng/g BW). Comparisons are between
phenotypes at the given dose(Values are± SEM,n=5).
Skeletal muscle is the major thermogenic tissue and the most metabolically active. It
is insulin-responsive and accountsfor 85% ofserum glucose uptake in the body. Therefore
it is important to examine the GLUT4transporter profile in myocytes. The total GLUT4

quantity was determined in the myocytes of +/db and db/db mice (Figure 5). The total
GLUT4 transporter quantity in vehicle-treated +/db animals was 0.58±0.04 OD units and

this subsequently increased with thyroid hormone treatment with the maximal response
occurring at20G ng Tj/g BW(0.744±0.020D units). However, at the supraphysiological
dose,the total GLUT4transporter quantity significantly decreased relative to mice receiving
200 ng Tg/g BW (0.664±0.04 vs. 0.744±0.02 OD units, respectively; p<0.05). Although

not significant at p<0.05,the total GLUT4 quantity observed in animals receiving 500 ng
Tj/g BW was apparently greater than vehicle-treated +/<i& mice(p<0.10). The increase in
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total GLUT4transporter quantity suggests that Tjinduces GLUT4 transporter expression
in normal animals.

The total GLUT4 transporter quantity in myocytes ofvehicle-treated

animals

was similar to that ofvehicle-treated normal animals(0.572±0.03 vs. 0.580±0.04 OD units,

respectively; p>0.05). Treatment with 100 or 200 ng Tj/g BW caused the total GLUT4

quantity to increase. At the supraphysiological dose(500 ng Tg/g BW),the total GLUT4
transporter quantity in db/db mice approached values observed in vehicle-treated +/db
animals (0.594±0.02 vs. 0.58±0.04 OD units, respectively; p>0.05). This suggests that
some GLUT4 induction at 100 and 200 ng T3/g BW doses occurred with thyroid hormone

treatment and T3 had a normalization effect on the total GLUT4 transporter quantities.
Also, attenuation responses were observed with supraphysiological T3 treatment. These

responses in db/db mice paralleled the pattern observed in +/db animals but always to a
lesser degree.

The distributions ofGLUT4transporters in the cytoplasm and plasma membrane were
also determined in skeletal muscle(Figures 6 and 7)and an expression pattern similar to
adipose tissue was observed. The baseline expression ofcytoplasmic GLUT4 transporter

in myocytes of vehicle-treated (0 ng T3/g BW)+/db animals was 0.268±0.03 OD units
(Figure 6). The cytoplasmic GLUT4 transporter quantity in myocytes of +/db xmcQ
increased linearly with treatments of100 and 200 ng T3/g BW. Treatment with 500 ng T3/g

BW also increased cjdoplasmic GLUT4 but to a lesser degree(0.402±0.03 OD units).
In db/db mice, the baseline expression of cytoplasmic GLUT4 in myocytes was
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Figure 6. Cytoplasmic content ofGLUT4 transporters in myocytes ofnormal{+/db)and
diabetic {db/db) mice treated with Tj(0, lOG, 200, and 500 ng/g BW). Comparisons are
between phenotypes at the given dose(Values are ± SEM,n=5).

0.326±0.03 OD units(Figure 6). The cytoplasmic GLUT4 quantity in vehicle-treated db/db
mice was not significantly different Xhm +/db animals but the quantity of cytoplasmic
GLUT4 m db/db mice decreased with all doses ofthyroid hormone(p<0.05). However,the

cytoplasmic GLUT4 content transporters ofdb/db mice approximated values ofvehicletreated +/db mice when treated with 500 ng Tj/g BW.
The baseline GLUT4transporter expression in the plasma membrane ofvehicle-treated

+/£/&mice was 0.312±0.03 OD units (Figure 7). The quantity of GLUT4 glucose

transporters associated with the plasma tnembrane in these animals decreased with thyroid
hormone treatment (p<0.05).

In vehicle-treated db/db mice, the baseline GLUT4

transporter quantity was less than vehicle-treated +/db mice(0.246±0.02 vs. 0.312±0.03
OD units, respectively; p<0.05). In contrast to normal animals, thjToid hormone treatment
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Figure 7. GLUT4 quantity associated with plasma membrane ofmyocytes ofnormal{+/db)
and diabetic(db/db)mice treated with T3(0, 100,200,and 500 ng/g BW). Comparisons
are between phenotypes at the given dose(Values are ± SEM,n=5).

increased the quantity of GLUT4 transporters associated with the plasma membrane in
db/db mice. The GLUT4 quantity with supraphysiological T3 doses approached values of
normal, vehicle-treated animals (0.302±0.02 vs. 0.312±0.03 OD units, p>0.05) which

suggests that T3 normalized db/db mice. The observed increases in GLUT4 transporters
associated with the plasma membrane as the cytoplasmic pool decreases suggests that in
db/db mice vesicular translocation occurs in response to thyroid hormone administration.

To further evaluate the possibilities ofTj-induced vesicular translocation in myocytes,

the quantity ofGLUT4 transporters associated with the plasma membranes were assessed

and reported as a proportion ofthe total cellular GLUT4 content. In vehicle-treated +/db
animals, the percentage ofGLUT4 was approximately 54±4%(Figure 8). Normalmice
showed dose-dependent decreases in the GLUT4transporter percentage associated with the
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Figure 8. Fraction ofGLUT4 associated with plasma membrane ofmyocytes ofnormal
{+/db) and diabetic {db/db) mice treated with Tj (0, 100, 200, and 500 ng/g BW).
Comparisons are between phenotypes at the given dose(Values are ± SEM,n=5).

plasma membrane up to 200 ng Tj/g BW. The percentage of GLUT4 transporters
associated with the plasma membrane ofmyocytes in vehicle-treated db/db animals was less
than the vehicle-treated +/db mice(43.3±3% vs. 54±4%,respectively; p<0.05). Treatment

with thyroid hormone increased the percentage ofGLUT4 transporters associated with the
plasma membrane at all doses in db/db animals and surpassed the percentage of GLUT4

transporters associated with the plasma membrane of^/db mice at the 100 ng T3/g BW dose

(58.2±6% vs. 43±9%,p<0.01). However,at the supraphysiological dose,the percentage
of GLUT4 transporters associated with the membrane approached the percentage values
observed in vehicle-treated +/db animals (57.2±7% vs. 54±8%, p>0.05). These data

suggest that T,stimulates GLUT4 transporter translocation to the plasma membrane of
myocytesin db/db mice. The significant increase in the percentage ofGLUT4 transporters
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associated with the plasma membrane observed in myocytes from db/db mice is important
since this may facilitate increased glucose uptake in skeletal muscle.

T3treatment regulated the induction and vesicular translocation mechanisms in adipose
tissue oidb/db animals. T3 did not induce GLUT4 expression in +/db mice since total
GLUT4 expression decreased with treatment but did induce GLUT4 expression in db/db
mice. Thus,the decrease in cytoplasmic GLUT4 that was observed within adipocytes of
+/db animals may be attributed to either decreased induction of the GLUT4 glucose

transporter or decreased plasmamembrane intemalization. In vehicle-treated +/db animals,
the cytoplasmic GLUT4 quantity decreased with T3 whereasin db/db mice it increased. The
decreased cytoplasmic GLUT4 transporter quantity observed in vehicle-treated db/db
animals may reflect a problem with the induction process. Vehicle treatment in db/db mice

represents "hypothyroid" concentrations and treatment with T3 restores the animal to
functionally euthyroid T3 levels. Thus, with T3 treatment, GLUT4 transporter levels

approximate those ofnormal animals. The plasma membrane associated transporter quantity
in normal mice was unaltered with T3 doses. Although translocation ofthe cytoplasmic
GLUT4towardsthe plasma membrane was observed in db/db animals with thyroid hormone
treatment, a decrease in membrane-associated GLUT4 transporter quantity with a

concomitant increase in the c54oplasniic pool was observed at the supraphysiological doses

which may represent either attenuated T3 responsiveness or accelerated intemalization of
GLUT4 transporters.

Alterations in skeletal muscle GLUT4 expression have been reported in NIDDM

subjects. However, the current study reports induction ofGLUT4 transporters by T3 in

37

translocation in myocytes ofdb'db animals. A decrease in the cytoplasmic pool with a
concomitant increase in the GLUT4 transporter quantity associated with the plasma
membrane was also observed. This suggests that Tj regulates GLUT4 transporter
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Figure 9. Core body temperatures of normal {-v/dh) and diabetic {db/dh) mice treated
with Tj(0, 100,200,and 500 ng/g BW).
dose(Values are ± SEM,n=5).
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temperatures of+/<i&mice on day 10. These data confirm that T3 treatment increasescore

body temperatures in normal mice and represent the normal thermogenic response.
The core body temperatures of vehicle^treated db/db mice were less than those of
normal animals(29.52±0.23''G vs. 30.44±0.10°C,respectively; p<0.01). Thyroid hormone
treatment induced dose-dependent increases in core body temperatures ofvehicle-treated
db/db animals with a maximal response being reached at 200 ng Tj/g BW. The 500 ng Tj/g
BW dose caused no further change. These data show that the core body temperatures of
vehicle-treated

mice are less than +/db mice and suggest that T3 treatment increases

core body temperatures in db/db mice to levels of+/db animals. Core body temperatures
ofdb/db mice were,however,lower than similarly treated +/db mice at all doses suggesting

Tjhyporesponsiveness and/or reduced thermogenic capacity.
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Figure 10. Daily core body temperatures ofvehicle-treated normal(+/db)and diabetic
{db/db)mice. Comparisons are between phenotypes at the given day(Values are ± SEM,
n=5).
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Figure 10 shows that the core body temperatures of vehicle-treated +/db mice

gradually declined throughout the study resulting in day 10 values less than those observed
on day 1(32.4±0.19°C vs. 30.44±0.WC,respectively; p<0.05)while vehicle-treated
animals showed a similar but not statistically distinguishable decrease (30.5±0.11°C vs.

29.5±0.23°C,respectively, p>0.05). Atemperature decrease observed in +/<iZ> animals was

unexpected and cannot be explained using available data.
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Figure 11. Daily core body temperatures of normal (+/db) and diabetic (db/db) mice
treated with 100 ng Tj/g BW. Comparisons are between phenotypes at the given day
(Values are ± SEM, n=5).

The core body temperatures of

mice treated with 100 ng Tj/g BW remained

unchanged through day 6, but decreased on days 7 through day 10 (Figure 11). In db/db
animals receiving the replacement dose, core body temperatures increased and a maximal
response was observed on day 6. In a pattern similar to +/db mice, the temperatures in
db/db animals decreased on days ? through day 10. The fluctuations in temperature may
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be attributed to induced stress resulting from handling and methods in obtaining colonic

temperature readings, however this was not tested.
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Figure 12. Daily core body temperatures of normal(+/db)and diabetic {db/db)xmcQ
treated with 200 ng Tj/g BW. Comparisons are between phenotypes at the given day

(Values are ± SEM,n=5).
Daily core body temperatures were recorded to assess the chronology ofthermogenic
responses. Figure 12showsthe responses of+/ri& and

mice treated whh 200 ng Tg/g

BW and these representthe mammal metabolic responses recorded for all tremment groups.

The maximal response was observed on day 4(32.52±0.16°C) after which core body
temperatures continued to decrease Until day 8 where they remained constant until day 10

(31.04±0.18°C). ladb/db mice,the baseline core body temperatures were considerably less

than those of normal mice, but T3 treatment caused daily increases in core body
temperatures with the maximal response being observed on day 6. Temperatures then

decreased until day9 where they remained constant through day lOi. Similar chronological
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responses to Tj-induced thermogenesis were observed in both +/dh and db/db mice.
However,
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Figure 13. Daily core body temperatures of normal(+/dh) and diabetic (dh/dh) mice
treated with 500 ng Tj/g BW. Comparisons are between phenotypes at the given day
(Values are± SEM,n=5).

The core body temperatures from -Mb and dh/dh mice treated with 500 ng T^/g BW
were also recorded on days 1 through 10(Figure 13). The temperature changes in these

animals paralleled those observed in mice treated with 200 ng T,/g BW. The core body

represent the heat that is dissipated. As core body temperatures increased in response to
on

temperatures occurred on days 7-10. Excess heat is dissipated on days 7through 10.

Mh and dhMh mice were recorded on days 7-10. Figure 14 shows that the radiant
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temperatures of+/(i& mice increased in response to

Tj/g BW. There was an increase in radiant heat as the body core temperatures decreased.
As core body temperatures of+/db and db/db mice decreased bn day 7 oftreatment, the
doses. .

.
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Figure 14.
To (0, 100, 200, and 500 ng/gBW). Comparisons are between phenotypes at the given dose
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The radiant temperatures oidb/db mice increased inresponse to T3 at all doses (Figure
14).

animals (30.96±0.I4°C vs. 31.56±0.12''C, p^O.05). The maximal response occurred at 500
ng Tj/g BW at wliich the radiant temperature was also greater than f /db mice. These data
show that Tj induces thermogenesis inboth /db and

animals. The increase in radiant

temperature as the core body temperatures decreased occurred in order to dissipate the
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excess heatto thermoregulate the core temperature. This pattern was also observed in +/db
•niice..:

..

The radiant temperatures from !/dh mice treated with vehicle and 100,200,and 500
ng Tj/g BW were recorded on days 7through 10. An increase in radiant temperature was

observed at the 100 ng Tg/g BW dose in \ /dh and dh/dh animals on days 7 and 8(data not
shown), a pattern similar to the group of mice treated with 200 ng Tj/g BW. However,

radiant temperatures of +/dh mice decreased on days 9-10 and were not different than

temperatures recorded on day 7 whereas radiant temperatures in dh/dh mice increased
through day 10.
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200 ng Tj/g BW. Comparisons are
n=5). . \

are ±

are shown since maximal thermic responses were observed at these doses. Figure 15 shows
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that the radiant temperature in '-/dh mice on day 7 was 34.1±0.10''C and continued to
increase until a maximal response was observed on day 10(36.68±0.22"C). In dh/dh mice,
radiant temperatures increased with Tg treatment and the maximal response was observed

These observations suggest that, with T,treatment, radiant temperatures ofdb/dh mice

approach normal and imply that dh/dh animals are utilizing as much energy as -\-/dh animals
to drive thermogenesis.
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Figure 16. Radiant temperatures ofnormal{+/dh)and diabetic(dh/dh)mice treated with
500 ng Tj/g BW. Comparisons are between phenotypes at the given day(Values are ±
SEM,n=5).
The radiant temperatures of -/dh mice treated with 500 ng Tj/g BW were also

to that observed in mice treated with 200 ng T3/g BW. The day 7 radiant temperatures of
normal animals were 34.96±0.24"C with the maximal response observed on day 9 and a
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decrease on day 10. In db/db mice,the radiant temperature on day 7 was 34.94±0.16°C and

the maximal response observed on day 10 was greater than that of +/(i6 animals
(36.88±0.13''C vs. 35.76±0.08''C, p<0.05). These observations suggest that Tjtreatment
increases the radiant temperatures ofdb/db mice beyond those ofnormal animals implying

that greater energy is being utilized and that db/db animals are dissipating more heat than
+/db mice. The concomitant decrease in core body temperature observed in +/db mA db/db

animals is likely due to thermoregulation in order to maintain a low core temperature.

Serum Glucose Determination

Serum glucose concentrations were evaluated in +/db and db/db animals in order to

determine if thyroid hormone treatment influenced serum glucose levels. The baseline
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Figure 17. Serum glucose concentrations of normal (+/<i&) and diabetic {db/db) mice
treated with Tj(0, 100,200, and 500 ng/g BW). Comparisons are between phenotypes at
the given dose(Values are ± SEM,n=5).
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glucose levels in vehicle-treated +/<5?Z> mice were 260.2±25.3 mg glucose/dL and these
remained relatively constant with T3 treatment(Figure 17). In db/db mice, the baseline
glucose concentration was 592.0±63.0 mg glucose/dL and this is considered severely
hyperglycemic. Serum glucose levels decreased with T3 treatment in a dose-dependent
fashion. At 500 ng Tj/g BW,serum glucose levels decreased approximately 42% when

compared to vehicle-treated mice(592.0±63.0 vs. 344.5±31.4 mg glucose/dL,respectively;
p<0.01)which indicates that T3treatment improved the glycemic status in db/db animals.

Respiratorv Quotient(ROI Determination

The respiratory quotient,RQ,(ml CO2/ ml O2)was monitored daily in +/db and db/db
mice over a nine day period in order to determine the effect T3 treatment might have on
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Figure 18. Respiratory quotients(RQ)ofnormal(+/db)and diabetic{db/db)mice treated
with T3(0, 100,200,and 500 ng/g BW). Comparisons are between phenotypes at the given
dose(Values are ± SEM,n=5).
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metabolic substrate utilization. The RQ of +/db mice treated with 0 ng T3/g BW was

0.78±0.03 (Figure 18) which suggests that a combination of proteins, lipids and
carbohydrates were potentially being used as the metabolic substrate. With T3 treatment,
the RQ value decreased to 0.74±0.01 which suggests a shift toward more fat or protein
catabolism. In vehicle-treated db/db mice, the RQ was 0.87±0.05 (Figure 18). This

indicates that substantially more carbohydrates were being used as a metabolic substrate

than is typically used by +/db animals. With increasing doses ofthyroid hormone,the RQ
decreased significantly. Diabetic mice treated with 100 ng T3/g BW had a respiratory
quotient that was less than vehicle-treated animals(0.78±0.02 vs. 0.87±0.05, p<0.05)and

suggests thatthe primary substrate being utilized had shifted from carbohydrates to fats or
proteins. The RQ values of db/db mice treated with either 200 or 500 ng T3/g BW
approached those ofvehicle-treated +/db animals(0.76±0.03 vs. 0.74±0.03,p>0.05)and
indicates that the db/db mice were undergoing fat catabolism. This also suggests that the
diabetic mice have undergone normalization in substrate utilization.
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CHAPTER FOUR: DISCUSSION

The insulin-regulatable GLUT4 transporter is expressed in skeletal muscle, adipose

tissue, and cardiac muscle(Pessin and Bell 1992;Mueqkler 1994; Stephens and Pilch 1994)
and regulates glucdsd uptake in those target tissues. The present study investigated whether

thyroid hormone treatment could restore the insulin effects on GLUT4 glucose transporter
induction and/or translocation in the insulin-resistant

mouse. This effect was assessed

by examining the total GLUT4 quantity as an indicator ofthe induction process and the
cellular GLUT4 distributions Which represent translocation within the cell.

These

phenomena were evaluated in lean C57BL/KsJ +/db mice and obese-diabetic G57BL/KsJ
db/db nice,which are insulin-resistant(Hummeletal. 1966), Ts-resistant, and functionally

hypothyroid(Fehn er a/. 1988).
Matthaei et al.(1995)shoWed that the total GLUT4 glucose transporter quantity in

adipocytes ofmale Sprague-Dawley fats decreased in hypothyroid animals, but increased
in hyperthyroid rats. These results agree with data presented in this study since the

functionally hypothyroid and Tj-resistant db/db mice are brought to functionally euthyroid
status using hyperthyroid doses of T3. The total GLUT4 quantity was assessed in the

adipocytes of

and db/db mice in order to determine ifadministration ofT3 stimulated

GLUT4 induction. Total GLUT4 transporter quantity in +/<i& niice remained unchanged
with increasing doses ofT3 which suggests that induction the GLUT4 transporter is not
likely under direct regulation at normal physiologic concentrations of T3. However,

attenuation was observed at the maximal dose ofT3. In

mice,which are T3-resistant

and functionally hypothyroid, the total GLUT4 quantity was 50% that ofvehicle-treated
+/db animals and this increased 2-fold with T3 treatment and approached levels equivalent
to those ofvehicle-treated +/db animals(Figure 1). The findings in this study are consistent

with results showing that T3 increases total GLUT4 protein expression(Cask et al. 1990).

This suggests that T3 stimulates GLUT4 induction and normalizes GLUT4 quantities in
db/db mice. A reduction in the degradation rate to accountfor increased GLUT4 cannot,
however, be discounted.

Zorzano etal.(1996)showed in STZ-induced diabetic(insulin-deficient)Wistar rats

thatthe quantity ofGLUT4 decreased in the cytoplasm ofadipocytes and increased in the
plasma membrane with increased insulin concentrations. This author suggests that insulin
promotes redistribution ofthe glucose transporter to the plasma membrane. Although these
results explain the established effects ofinsulin,the current study addresses thyroid hormone
effects and the potential restoration ofinsulin action in a model for NIDDM. In the current
study, T3 mimics the effects Zorzano er al.(1996)reported for insulin action. Zorzano's

results are in agreement with the results observed in the +/db mice from this study since
these animals remain insulin-responsive. Gytoplasmic and membrane-bound GLUT4 in

adipocytes of +/db mice remained Constant with T3 treatment and only the cytoplasmic

portion decreased with supraphysiological doses(Figures 2 and 3). This represents normal
expression, GLUT4 transporter recycling, and regulation in a normal endocrine
environment. However,the decreased cytoplasmic GLUT4 at the 500 ng Tj/g BW dose

suggests increased degradation of membrane components or attenuation of GLUT4
synthesis. Such attenuation is a blunted response typically observed within systems that
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have been pushed to physiological extremes.

Previous studies on adipocytes from insulin-deficient diabetic rats(Kahn et al. 1989;
Berger etal 1989)and in studies using 3T3-L1 adipocytes cultured in vitro without insulin
(Calderhead etal. 1990), showed that cytoplasmic GLUT4 quantities were less than those
ofnormal rats and insulin-treated cells, respectively. Decreased expression ofthe GLUT4

transporter has also been documented in NIDDM patients as well as in diabetic animal
models(Koranyi et al 1990;Kahn 1996). The decrease in cytoplasmic GLUT4 number
reduces their availability to be mobilized to the plasma membrane and could explain the
lower plasma membrane content. It has also been reported that insulin-stimulated GLUT4
translocation is impaired in adipocytes fi^Om NIDDM individuals (Ciaraldi

al 1991).

However,the mechanism by which translocation is regulated has not yet been explained and

has recently received much attention as being the potential site ofregulatory defects(Kahn
1996). The current study showed that cytoplasmic GLUT4 in vehicle-treated db/db mice
was 50% less than vehicle-treated +/£/& mice. This quantity decreased in response to T3

treatment but increased 2-fold with the 500 ng T3/g BW dose and therefore approached
levels ofvehicle-treated +/db mice(Figure 2). As cytoplasmic GLUT4 is disproportionately

depleted, a concomitant increase in the quantity ofmembrane-bound GLUT4 is observed
which approaches that ofvehicle-treated +/db mice(Figures 2, 3). This suggests that T3
facilitates GLUT4translocation fi-om the cytoplasm to the plasma membrane and normalizes

GLUT4 within adipose tissue offunctionally "hypothyroid" animals.

The proportion ofGLUT4 glucose transporters associated with the plasma membrane
was calculated in +/db and db/db mice to determine ifthyroid hormone administration plays
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a role in the trafl&cking ofthe GLUT4 transporter, specifically in the translocation process.

Thistype ofanalysis has not been reported previously,thus there are no studies with which
to compare the current data. The percent ofthe GLUT4 transporter population associated
with the plasma membrane ofadipocytes in +/db mice did not change with T3 treatment

(Figure 4). Thyroid hormone either did not alter the GLUT4 transporter turnover or it
equally affected the rates ofintemalization and association ofGLUT4 transporters with the
plasma membrane. Although the absolute amount ofmembrane-bound GLUT4 in db/db
mice wasless than in +/db mice,the percent ofGLUT4glucose transporters associated with

the plasma membrane was similar to that of +/db mice (Figure 4). This shows that the
membrane-bound GLUT4 quantity in relation tO the total GLUT4 in db/db mice is

proportional to that of+/db animals, thus,the percentage is scaled down proportionately
in db/db mice. In db/db animals treated with T3,the percent ofGLUT4 associated with the

plasma membrane increased suggesting that T3 may regulate GLUT4 translocation from the
cytoplasm to the plasma membrane. Since the final proportions approached those of+/db
mice, it appears that T3 normalizes the GHJT4 quantity associated with the plasma
membranes ofdb/db mice. Thyroid hormone does not induce the synthesis ofadditional
GLUT4in +/db mice nor is the cellular distribution affected. As a result ofovercoming T3

resistance in db/db mice, T3induces GLUT4 synthesis resulting in increased cellular GLUT4

content. The cytoplasmic population consequently is redistributed towards the plasma
membrane suggesting that T3 restores the translocation process.
GLUT4transporter expression and subcellular distribution were assessed in myocytes

because skeletal muscle is a metabolically active tissue which utilizes approximately 85%
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oftotal ^cos6^ail^l6^

is tlie m^opsite for glucose disposal and is the

majof site ofinsulin:resistance witlun NiDD|M%bjects

nr/. 1996). The total

GrLUT4 quantity was assessed in the myocytes of +/db and db/dh mice to deternune if
thyroid hormone administration stimulated GLUT4 induction. Total GLUT4 quantity in
\ /dh mice increased with T3treatment at physiological doses but to a lesser degree with the

supraphysiological dose. This shows that Tjfacilitates GLUT4 transporter induction. In
vehicle-treated db/db mice, the total GLUT4 transporter quantity was similar to that of
vehicle-treated -/db animals and total GLUT4 quantity also increased with T,treatment
showing that Tjinduces the GLUT4 transporter.

The current study proposes a model whereby T,either overcomes thyroid hormone
resistance and restores the insulin response in target tissues ofdb/db mice or T,has a direct

effect in GLUT4 transporter regulation. If the insulin response is restored with Tj
treatment,the results from the current study then contradict published reports which show

that GLUT4 transporter expression within skeletal muscle remains unchanged in response
to insulin treatments(Kahn 1996;Hainhault etal. 1991;Pedersen et al. 1990). A possible
reason for this discrepancy is that all animal and human subjects were fasted at least 8 hours

prior to testing and fasting causes a decrease in thyroid hormone levels thereby rendering
the animals hypothyroid. Weinstein el al.(1991) showed that T,could induce GLUT4

expression in skeletal muscle of hypothyroid non-diabetic animals that were restored to
euthyroid status. Since the animals werefasted priorto tissue collection,the GLUT4 values
and thyroid levels are not accurate representations ofanimals in a non-fasting state. At the

supraphysiological dose,total GLUT4in myocytes ofdb/db mice approached GLUT4 levels

found in vehicle-treated+/<i& animals (Figure 5). This suggests that total GLUT4 is
normalized in dh/db mice that have overcome thyroid hormone resistance. Although total

GLUT4 quantities in vehicle-treated +/db and db/db mice were not different(Figure 5), the
subcellular distributions were different in the two phenotypes(Figures 6, 7). However, T3

treatment allows for "normal" GLUT4 expression and a more appropriate distribution of

subcellular GLUT4 quantities. These data show that T3 stimulates GLUT4 induction and

likely plays a role in either the transcriptional or translational processing ofthe GLUT4
glucose transporter.

The quantity ofcytoplasmic GLUT4in myocytes of+/db mice increased in response
to thyroid hormone treatment and these results are consistent with the published literature
(Casla et al. 1990;Weinstein et al. 1991; Weinstein et al. 1994). Induction ofGLUT4 has
been established above, but the increased cytoplasmic quantity can also reflect increased

intemalization ofplasma membrane components(Figure 6). This response contrasts with
observations made in adipocytes of+/db animals and suggests tissue-specific responses to

T3. The membrane-bound GLUT4 in +/db mice decreased with T3. This suggests
attenuation phenomena or increased GLUT4transporter intemalization as was seen with the

adipocytes of +/db mice. Based on the observations within myocytes, T3 appears to
regulate GLUT4transporter induction and vesicular translocation at a basal level whereby
T3 exhibits its permissive action under normal physiological conditions.
Several studies have shown that cellular GLUT4 expression levels(either protein or
mRNA)are unchanged in the skeletal muscle ofdiabetic subjects(Kahn 1996;Hainhault et

al 1991;Pedersen etal 1990)including the quadriceps of5 week-old db/db mice(Koranyi
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et al. 1991). In each ofthese studies, only the plasma membrane-associated content of
GLUT4 glucose transporters has been shown to be altered in skeletal muscle. However,
results from the current study show that the cytoplasmic GLUT4 in db/dh mice is greater

than the cytoplasmic GLUT4 contentfound within ^/dh mice and these quantities decrease

inresponse to Tj. This indicates that the pool ofcytoplasmic GLUT4in myocytes of8-10
week old db/db mice is regulated by Tj. These results are contrary to reports ofunalterable

GLUT4 expression in quadriceps of 5 week old

mice. This discrepancy can be

attributed to the age differences ofthe mice. Fehn etal(1988)reported that the onset of
a defect in Tg responsiveness occurs after 6 weeks ofage thus Koranyi etal(1990)missed
the onset period and obtained results from animals not yet displaying the Tg-resistance.

Also, a concomitant disproportionate depletion in cytoplasmic GLUT4 quantities was
observed while membrane-bound GLUT4increased in db/db mice(Figures 6, 7). This was

similar to the pattern observed in adipocytes and indicates that T3 may regulate GLUT4
translocatioh from the cytoplasm towards the plasma membrane. This observation is

extremely important since skeletal muscle requires the GLUT4 transporter for the majority
ofglucose uptake. Although T3 regulation ofGLUT4 translocation has not been reported
in the literature,the results reported here are consistent with the depletion ofa cytoplasmic

vesicular pool in response to a hormonal signal(Weinstein et al 1994). Therefore, T3 is
herein proposed as a regulator ofGLUT4 translocation process.

At the supraphysiological dose ofT3(500 ng/g BW),the membrane bound GLUT4
transporter quantity in db/db mice decreases, although it still remains greater in comparison
to the vehicle-treated counterpart.

As the membrane-bound quantity decreases
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(approaching values similar to the baseline expression levels of+/db vehicle-treated mice),
the quantity ofcytoplasmic GLUT4-containing vesicles increases also approaching values
similar to +/db vehicle-treated mice. This suggests a normalization phenomenon within the
skeletal muscle in response to thyroid hormone treatment.
The current study establishes that Tjincreases GLUT4 transporter induction because
an increase is seen in the total cellular quantity ofGLUT4 transporters. These data agree

with the findings of Casla et al. (1990) and Weinstein et al. (1991). More recently,
Torrance et al.(1997)showed that Tjregulates GLUT4 expression at the transcriptional
level in one muscle fiber type and increased both membrane-bound GLUT4 quantities and
GHJT4 mRNA. However,Torrance et al.(1997)failed to recognize that T3 regulates the
redistribution ofthe GLUT4transporterfrom the cytoplasm to the plasma membrane. This

redistribution ofGHJT4 transporters towards the plasma membrane is important since it
may be the pathway for increased cellular glucose uptake.

In normal mice, the percent ofthe GLUT4 transporter associated with the plasma
membrane ofmyocytes decreased with thyroid hormone treatment and shows that T3 altered
GLUT4 transporter turnover(Figure 8). Perhaps overloading the system with an excess

number of GLUT4 transporters surpasses the quantity of docking complexes available
within the cell leading to accumulation in the cytoplasm. Alternatively, intemalization of

membrane components may be accelerated as part ofan increased recycling rate phenomena.
The percent of GLUT4 glucose transporters associated with the plasma membrane of
vehicle-treated db/db mice wasless than that ofvehicle-treated +/<i6 mice(Figure 8). This

quantity increased with thyroid hormone treatment and indicates that T3 regulates GLUT4
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vesicular translocation from the cytoplasm towardsthe plasma membrane. Thisis extremely

important since the increased percent ofGLUT4 transporters associated with the plasma
membrane indicates translocation and docking and suggests a greater probability that
GLUT4 transporters have fused with plasma membrane. Increased fusion of GLUT4

transporters with the plasma membrane of myocytes would facilitate increased glucose

uptake which would provide the substrate for increased thermogenic activity in the skeletal
muscle. Although these data show that T3 regulates the translocation mechanism from the
cjtoplasm to the plasma membrane,one cannot say that the GLUT4 transporters within the
vesicle membrane are incorporated into the plasma membrane. Thus,the vesicular fusion
mechanism warrants fiirther investigation.

The current study establishes that T3 plays a role in GLUT4 transporter regulation.

Thyroid hormone induced the GLUT4 transporter in both adipocytes and myocytes, but to
varying degrees. This shows the tissue specific responses to T3in relation to GLUT4. Also,
T3 promoted the translocation ofcytoplasmic GLUT4towards the plasma membrane in both
myocytes and adipocytes and thus contributed to the increased plasma membrane GLUT4
content. This is particularly important in relation to NIDDM since this increased quantity

may facilitate increased glucose uptake within these cells. The increased glucose uptake
would thus provide the cells, particularly myocytes with a substrate that can be utilized for

metabolism and thermogenesis.
The core body temperatures in +/db and db/db animals were measured to determine
the effect ofT3 treatment on thermogenesis. Core body temperatures of+/db mice were

greater than db/db animals which is what is expected since diabetic animals exhibit impaired
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thermogenesis(Hummel e^a/. 1966). The temperatures of both +/db and db/db mice
increased with thyroid hormone treatment demonstrating thermogenic responses in both

phenotypes. These results are similar to those reported by Oh and Kaplan(1994)for the
phenotypically-related obese (pb/ob) mouse model. Obese ob/ob mice are hypothermic
making them similar to db/db animals (Oh and Kaplan 1994; Hummel

al. 1966).

However, ob/ob mice are hypothyroid, meaning that T3 levels are decreased, yet are still

responsive to T3. In contrast,

mice are hyperthyroid but exhibit hyporesponsiveness

to the action ofthyroid hormone, which is indicative ofT3-resistance(Fehn et al. 1983,

1988). Thyroid hormone treatment elicits thermogenic responses in both ob/ob mice and
in db/db mice although db/db animals require supraphysiological doses to be effective.

Thus,T3increases the core body temperatures in both animal models. When the core body

temperatures were monitored throughout the ten day study, animals ofboth phenotypes
receiving T3 doses of200 and 500 ng/g BW,exhibited declining temperatures on days 7
through 10. This, however,does not reflect a decrease in thermogenesis because lower core
body temperatures were accompanied by higher radiant temperatures. A reasonable
explanation for this observation is that the animals maintain their core body temperatures

by dissipating excess heat produced in response to T3 treatment as radiant heat. This
phenomenon represents normal T3-induced thermoregulation and accounts for the changes

in temperature observed within these animals.
Radiant temperatures have not previously been reported for such studies, therefore
data from this study cannot be compared with published reports since this is a novel

approach to account for thermogenic activity. It does, however, account more accurately
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for increases in metabolism associated with T3treatment. Radiant temperatures in +/db and

db/db mice both increase with thyroid hormone treatment. However,the increase in radiant

temperature was greatest in db/db animals. The increase in radiant temperatures might be
potentially explained by increased thermogenic capacity in response to increased GLUT4
expression in the plasma membranes of myocytes. This increase in GLUT4 transporters
would account for increased glucose uptake by myocytes which would then utilize the

additional substrate in subsequent heat production(thermogenesis). Thyroid hormone also

has been shown to stimulate membrane permeability to ions as well as induce Na^/K^ pumps
in skeletal muscle, both ofwhich are believed to play a role in the thermogenic response

(Voldstedlund et al. 1995). The increase in thermogenic activity may also be associated
with higher C54oplasihic glucose concentrations due to Tj-induced GLUT4 vesicular fusion

(integration)with the plasma membrane ofmyocytes. Thus, Tj-induced GLUT4 expression
in the plasma membrane ofmyocytes may support thermogenic activity.
Hyperglycemia is characteristic ofNIDDM individuals since glucose uptake is not
adequately handled due to decreased insertion ofthe insulin-regulatable GLUT4 transporter
into cell membranes. In the cuirent study, serum glucose levels were examined to determine

ifthyroid hormone treatment improved the glycemic status ofdb/db mice. Serum glucose
levels ofnormal animals remained unchanged with T3treatment which suggests that T3 does

not affect the normal glucose handling mechanism in insulin-responsive animals(Figure 17).
However,serum glucose concentrations in vehicle-treated db/db mice were approximately
50% greater than in ^/db animals, as could be expected for animals displaying insulin
resistance. Thyroid hormone decreased glucose concentrations about 40% which suggests
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increased glucose utilization or restoration ofthe insulin response. Although still considered

hyperglycemic,the glycemic status ofdb/db animals wasimproved significantly with thyroid
hormone treatment. This suggests that tissues were able to take up glucose, however which
tissue specifically does this remains to be determined and warrants further study.

One approach to this problem might be to evaluate substrate utilization which
accompanies the redistribution ofGLUT4. The respiratory quotient(RQ)is an indicator
ofwhich substrate is being utilized asthe fuel source within the organism. In this study,the

respiratory quotient was determined to see ifthyroid hormone treatment causes a shift in the
mefabolic substrate utilized by +/db and db/db animals. The RQ values of+/db mice
decreased in response to thyroid hormone treatment to levels suggestive ofa combination
ofcarbohydrates, proteins, and fats as substrate sources(Figure 18). However,the RQ in
db/db mice shifts from 0.87± 0.05, which indicates carbohydrate as the predominant
substrate source to 0.76±0.03 which indicates increased utilization offats, proteins, or both

as the metabolic substrates in response to thyroid hormone treatment. Evidence from a

previous study wherein the adipocyte volumes ofdb/db rmcQ decreased in response to T3
suggests that fats were the primary source of energy (Estrada unpublished results).
However,the decrease in serum glucose levels with T3 treatment in db/db mice from the
current study suggests that there is substantial uptake but not utilization as a metabolic

substrate, informal examination ofUvers m db/db mice suggests increased deposition offats
which may be attributed to increased hepatic glucose uptake leading to enhanced lipogenesis
(data not shown). Although the glucose transporters in hepatocytes are not insulin
regulatable, the lipogenic enzymes still remain inducible by T3 and may account for the
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increased disposal ofglucose from the serum. However,the RQ values in the db/db mice

treated with supraphysiological doses ofthyroid hormone approached those of vehicletreated +/db mice and suggest, once again,that normalization has taken place.
The RQ values indicating a shift to fat catabolism do not support the observation of

increased membrane-associated GLUT4 transporters in myocytes facilitating increased

cellular glucose uptake and utilization. An explanation for increased GLUT4 associated
with the plasma membrane in the absence ofglucose utilization may be that the GLUT4
transporter-containing vesicles dock with the plasma membrane and are isolated with plasma
membrane fractions. The docked vesicles, however, may not be fused and therefore the

GLUT4 transporters are not integrated into the plasma membrane. Thus,glucose uptake
by myocytes cannot be facilitated since the GLUT4 transporter is not inserted correctly.

However,the energy by which thermogenesis is fueled is probably provided by fatty acids,
an idea which is supported by an RQ shift indicating fat catabolism,in conjunction with an
increase in radiant temperatures. The mechanism by which the vesicles containing the
GLUT4 glucose transportersfiise with the plasma membrane warrants further investigation
to see ifthat step within the trafficking mechanism is defective within NIDDM subjects.
This study has demonstrated reduced total GLUT4 expression in adipocytes and

decreased GLUT4transporters associated with the plasma membranes ofmyocytes ofdb/db

mice but an increases in these quantities in response to exogenous T3. The current study
also demonstrated that T3treatment induces GLUT4glucose transporter redistribution from

the cytoplasm to the plasma membrane of adipocytes and myocytes in db/db mice.

Observations from adipocytes are consistent with studies by Zorzano et al.(1996),Rahn
■
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eta/(1989),and Berger etal.(1989). Gibbs eta/.(1995)dluded to a trafFickirig problem

in GLUT4 transgenic db/db mice in which GLIJT4 pverexpression could cpmpensate for
a trafficking defect. This is consistent with the proportional fusion from the cytoplasm to

the plasma membrane demonstrated in this study, but T3 corrects the GLUT4 distribution

in

mice. The transgenict^/£/& mice showed a marked decrease in hyperglycemia due

to increased glucose transport. However,Gibbs et al.(1995)did not evaluate the cellular
GLUT4 distribution in all tissues oftransgenic mice and the potential consequences of

increased glucose disposal by tissues that typically do not express the GLUT4 transporter.
More recently, Torrance et al. (1997) showed that T3 regulates GLUT4 transporter

expression atthe transcriptional level in hypothyroid rats made hyperthyroid. Although not

pointed out by the authors, T,was shown to regulate GLUT4 transporter translocation
because distribution differences in GLUT4 transporters are observed in response to T,
administration.

The results of the current study indicate that GLUT4 transporter

translocation from the cytoplasm to the plasma membrane is regulated by T3 in db/db mice

and is the first report ofsuch regulation. The increased thermogenic response observed in

this study parallels increased numbers ofGLUT4transporters in the plasma membrane of
myocytes but the RQ values do not support carbohydrate utilization as the metabolic
substrate for the thermogenic response. However, decreased serum glucose levels in dh/db

mice in response to T3treatment indicates that glucose is taken up but is not utilized as the
metabolic substrate for thermogenesis. The liver may take up the glucose via GLUT2

transporters which are not insulin-regulated. Absorbed glucose may then be converted to
fat and stored away. Ifthis is the case,this may imply that the GLUT4 glucose transporters

glucose uptake. The energyto drive the Observed metabolic responses is likely supplied by
fats. This study suggests amodel wherein high doses of T3 overcome thyroid hormone
resistance in the db/db mouse and restore GLUT4 transporter translocation.
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